Nautilus Biotechnology, Inc. (NAUT) stock intrinsic value fair value estimate & owner earnings analysis

Nautilus Biotechnology is a Seattle-based life-sciences tools company that has spent nearly a decade developing a single-molecule protein-sequencing platform, Nautilus Voyager, intended to let researchers profile proteins - including their many chemically modified forms, or 'proteoforms' - at a scale existing methods cannot match. The company has not yet generated material revenue. It began a paid Early Access Program in January 2026, offering fee-for-service analysis of a specific protein (tau, relevant to neurodegenerative disease research) to a small group of collaborators, and it plans to open the full Voyager platform for pre-orders in late 2026, with instrument installations at customer sites beginning in early 2027. Management is explicit that the Early Access work is not expected to produce material revenue on its own; it exists to build scientific credibility and prepare for the broader launch. Because there is essentially no revenue history, we could not build a conventional earnings-based valuation the way we would for an established operating business. Instead we anchored the valuation on what is verifiable today - the company's net cash and investments, and the pace at which it is spending them - set against the very early, not-yet-monetized commercial plan for Voyager. At its most recent balance sheet date the company held roughly $142 million in cash, cash equivalents and marketable securities, with no debt (its main liability is an office and lab lease, which does not affect this figure). Against roughly 127 million diluted shares, that is about $1.10 per share sitting in the bank. The company has been spending cash on research and launch preparation at a rate of roughly $50-54 million a year, including in the first half of 2026, so absent new revenue or financing, this cash funds a bit under three years of continued operations at the current pace. One fact worth flagging directly: the company's own investor materials two years ago pointed to a commercial launch in 2025; the current timeline has slipped to late 2026/early 2027. That slippage is a concrete, disclosed fact, not a guess, and it is the main reason we discount the newly stated 'late 2026' timeline further in the cases below rather than taking it at face value. Bear case (about $0.10/share): Voyager launches roughly on the newly stated timeline, but adoption is slow and, consistent with management's own current disclosure, early revenue stays immaterial through the period we can defend. The company keeps burning cash near its recent rate and, given the launch has already slipped once, needs further outside capital before the technology is proven out - diluting current holders substantially, or in the worst realistic outcome, winding down. There is no debt, so shareholders cannot end up owing money, but most of today's cash cushion is likely spent or diluted away before any payoff. Base case (about $0.90/share): the launch proceeds on the stated schedule, and the already-running Early Access Program converts into a real, if modest, paying customer base over the following few years - a gradual adoption curve typical for a first-of-its-kind scientific instrument. Because there are no signed pre-orders or contracted revenue on the books yet, we are not crediting a specific revenue ramp; this case essentially preserves most of today's net cash value, with cash burn moderating as initial commercial revenue appears, without yet building sustained, profitable operations within the next ten years. Bull case (about $2.25/share): the plan executes well - Voyager launches on schedule, current Early Access collaborators and new customers convert into recurring instrument-and-consumables revenue (the standard economics for lab-instrument makers), and the company reaches self-funding operations within ten years without needing further dilutive financing to survive. The company carries no borrowings, so no separate debt deduction was needed; the net cash figures above already reflect the balance sheet as it stands. Given how binary and unproven the business still is - real technology and real cash, but no demonstrated commercial revenue and a launch date that has already slipped once - the margin-of-safety price is set at a large discount to the base case, around $0.35 a share, reflecting the real chance the bear case is closer to what actually happens.